Price (delayed)
$8
Market cap
$1.1B
P/E Ratio
200
Dividend/share
N/A
EPS
$0.04
Enterprise value
$1.09B
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The
There are no recent dividends present for AUPH.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.